<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335706">
  <stage>Registered</stage>
  <submitdate>4/08/2010</submitdate>
  <approvaldate>9/08/2010</approvaldate>
  <actrnumber>ACTRN12610000643077</actrnumber>
  <trial_identification>
    <studytitle>Effect of silymarin in treatment of adverse effects of anti tuberculosis drugs.</studytitle>
    <scientifictitle>Evaluation of Silymarin in treatment of anti tuberculosis drug induced hepatitis in patients newly diagnosed with tuberculosis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nill</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Tuberculosis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Silymarin 420 mg per day,in three doses, It will start after diagnosis of drug induced hepatitis and stop after normalization of liver function tests, as oral tablets</interventions>
    <comparator>Lactose 420 mg per day,in three doses, It will start after diagnosis of drug induced hepatitis and stop after normalization of liver function tests, as oral tablets</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Normalization of liver function tests</outcome>
      <timepoint>Evaluation of liver function tests three times weekly from diagnosis of drug induced hepatitis (Drug induced hepatitis means 3 times elevation of liver enzymes with clinical symptoms or 5 times without symptoms.)until normalization of them.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of silymarin adverse effects i. e. nausea, vomiting, bloating, diarrhea, itching by patient questionnaires and daily checklist.</outcome>
      <timepoint>Continuously during administration of drug/placebo</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>New cases of tuberculosis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Infection with Human Immune deficiency virus 2. Infection with hepatitis B virus 3. Infection with hepatitis c virus 4.pregnancy 5. Breast feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/10/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Institute of Tuberculosis and Lung Disease (NRITLD)</primarysponsorname>
    <primarysponsoraddress>Dar Abad street, Niavaran, Tehran, post code: 1955841452</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti medical university</fundingname>
      <fundingaddress>Velenjak street, Evin, Tehran, post code: 1955841452</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti medical university</fundingname>
      <fundingaddress>Velenjak street, Evin, Tehran, post code: 1955841452</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti medical university</fundingname>
      <fundingaddress>Velenjak street, Evin, Tehran, post code: 1955841452</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Masih Daneshvari Hospital</sponsorname>
      <sponsoraddress>Dar Abad street, Niavaran, Tehran, post code: 1955841452</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adverse effects of antituberculosis drugs are frequent, sometimes with morbidity and even may be fatal, most serious of them is drug induced hepatitis.
As Sylimarin in rat model has been effective in prevention and treatment of hepatic adverse effects of anti tuberculosis drugs, we decide to investigate this study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Majid Majani</name>
      <address>National Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Dar Abad street, Niavaran, Tehran, post code:1955841452</address>
      <phone>+982126109590</phone>
      <fax />
      <email>marjani216@hotmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Majid Marjani</name>
      <address>National Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Dar Abad street, Niavaran, Tehran, post code:1955841452</address>
      <phone>+982126109590</phone>
      <fax />
      <email>marjani216@hotmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Majid Marjani</name>
      <address>Masih Daneshvari Hospital, Dar Abad, Niavaran, Tehran
Post code: 1956944413</address>
      <phone>+982126109590</phone>
      <fax />
      <email>marjani216@hotmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>